265 related articles for article (PubMed ID: 8809410)
21. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
22. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis.
Yoshida S; Harada T; Iwabe T; Taniguchi F; Mitsunari M; Yamauchi N; Deura I; Horie S; Terakawa N
Hum Reprod; 2004 Aug; 19(8):1821-5. PubMed ID: 15166129
[TBL] [Abstract][Full Text] [Related]
23. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
24. A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA.
Oh JW; Revel M; Chebath J
Cytokine; 1996 May; 8(5):401-9. PubMed ID: 8726669
[TBL] [Abstract][Full Text] [Related]
25. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
26. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.
Karczewska A; Nawrocki S; Breborowicz D; Filas V; Mackiewicz A
Cancer; 2000 May; 88(9):2061-71. PubMed ID: 10813718
[TBL] [Abstract][Full Text] [Related]
27. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.
Hallek M; Neumann C; Schäffer M; Danhauser-Riedl S; von Bubnoff N; de Vos G; Druker BJ; Yasukawa K; Griffin JD; Emmerich B
Exp Hematol; 1997 Dec; 25(13):1367-77. PubMed ID: 9406996
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage.
Taguchi Y; Yamamoto M; Yamate T; Lin SC; Mocharla H; DeTogni P; Nakayama N; Boyce BF; Abe E; Manolagas SC
Proc Assoc Am Physicians; 1998; 110(6):559-74. PubMed ID: 9824538
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.
Zhu YM; Webster SJ; Flower D; Woll PJ
Br J Cancer; 2004 Nov; 91(11):1970-6. PubMed ID: 15545974
[TBL] [Abstract][Full Text] [Related]
30. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression.
Oh JW; Van Wagoner NJ; Rose-John S; Benveniste EN
J Immunol; 1998 Nov; 161(9):4992-9. PubMed ID: 9794436
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
32. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
33. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.
Olbina G; Cieslak D; Ruzdijic S; Esler C; An Z; Wang X; Hoffman R; Seifert W; Pietrzkowski Z
Anticancer Res; 1996; 16(6B):3525-30. PubMed ID: 9042216
[TBL] [Abstract][Full Text] [Related]
34. Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor.
Fourcin M; Chevalier S; Lebrun JJ; Kelly P; Pouplard A; Wijdenes J; Gascan H
Eur J Immunol; 1994 Jan; 24(1):277-80. PubMed ID: 8020567
[TBL] [Abstract][Full Text] [Related]
35. Soluble interleukin 6 receptor is biologically active in vivo.
Mackiewicz A; Wiznerowicz M; Roeb E; Karczewska A; Nowak J; Heinrich PC; Rose-John S
Cytokine; 1995 Feb; 7(2):142-9. PubMed ID: 7780033
[TBL] [Abstract][Full Text] [Related]
36. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
[TBL] [Abstract][Full Text] [Related]
37. Growth inhibition by cholera toxin of human lung carcinoma cell lines: correlation with GM1 ganglioside expression.
Kaur G; Viallet J; Laborda J; Blair O; Gazdar AF; Minna JD; Sausville EA
Cancer Res; 1992 Jun; 52(12):3340-6. PubMed ID: 1375868
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
39. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo.
Saito M; Yoshida K; Hibi M; Taga T; Kishimoto T
J Immunol; 1992 Jun; 148(12):4066-71. PubMed ID: 1602143
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.
Nakanishi H; Yoshioka K; Joyama S; Araki N; Myoui A; Ishiguro S; Ueda T; Yoshikawa H; Itoh K
Am J Pathol; 2004 Aug; 165(2):471-80. PubMed ID: 15277221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
